Community-Led Monitoring AP Database AP Data Dashboard
A Review of the PA-824 Patent Landscape: A Scoping Report
Publications
January 31, 2014

A Review of the PA-824 Patent Landscape: A Scoping Report

PA-824 belongs to the nitroimidazoles class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was reported as early as 1993. PA-824 was discovered by Patho- Genesis Corporation, which was subsequently acquired by Chiron Corporation. Novartis AG acquired Chiron Corporation in 2006.

Download PDF

PA-824 belongs to the nitroimidazoles class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was reported as early as 1993. PA-824 was discovered by Patho- Genesis Corporation, which was subsequently acquired by Chiron Corporation. Novartis AG acquired Chiron Corporation in 2006. PA-824 is a pro-drug, which requires reductive activation of an aromatic nitro group before it becomes effective against TB bacteria.

Organizations:

Unitaid

Share article:

Related Resources